Conquering Diseases

Study Of An Investigational Drug To Treat Wounds Due To Dystrophic Epidermolysis Bullosa

Description

Seeking people aged 2 and older with Dystrophic Epidermolysis Bullosa with confirmed mutation(s) of the Type 7 collagen (COL7A1) gene for a study of an investigational drug for wound healing.

Overview

Participants in this study will have blood and skin samples collected for use in making the investigational drug that will be injected back into their skin during 2 and maybe as many as 4 study visits. During the first 15 months of the study there are about 11 study visits. Afterward, there may be annual follow-up study visits and blood tests for the remaining 14 years.

What we're hoping for

We are studying if an investigational drug made using the skin cells of the person being treated (cell therapy) is safe and effective in increasing collagen and preventing blisters and wounds for people with dystrophic epidermolysis bullosa (DEB).

Additional Information

ClinicalTrials.gov Identifier: Not Available

 Principal Investigator

Diana  Reusch, MD

UMass Memorial Health

 Study Contact

Dermatology  Research

774-455-4758

DermResearch@umassmed.edu

 Location

UMass Chan University Campus

55 Lake Ave North 

Worcester,MA 01655

508-856-8989